Cargando…
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection
In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to adding pegIFN-α, or (iii) standard-of-care (SOC...
Autores principales: | Waldenström, Jesper, Westin, Johan, Nyström, Kristina, Christensen, Peer, Dalgard, Olav, Färkkilä, Martti, Lindahl, Karin, Nilsson, Staffan, Norkrans, Gunnar, Krarup, Henrik, Norrgren, Hans, Rauning Buhl, Mads, Stenmark, Stephan, Lagging, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864304/ https://www.ncbi.nlm.nih.gov/pubmed/27167219 http://dx.doi.org/10.1371/journal.pone.0155142 |
Ejemplares similares
-
Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
por: Waldenström, Jesper, et al.
Publicado: (2016) -
Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3
por: Alsiö, Åsa, et al.
Publicado: (2012) -
Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3
por: Rembeck, Karolina, et al.
Publicado: (2012) -
A Novel Fibrosis Index Comprising a Non-Cholesterol Sterol Accurately Predicts HCV-Related Liver Cirrhosis
por: Ydreborg, Magdalena, et al.
Publicado: (2014) -
Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection
por: Alestig, Erik, et al.
Publicado: (2011)